Onkologie. 2022:16(3):115-117 | DOI: 10.36290/xon.2022.022

New potential checkpoint inhibitors in cancer therapy

Jindřich Kopecký
Klinika onkologie a radioterapie, LF a FN Hradec Králové

Over the last decade, immunotherapy has been established as part of various treatment algorithms across solid tumors. And although the use of checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 receptors and anti-PD-1 ligand provides a therapeutic benefit, there is still a large group of patients in whom this therapy is not effective. Further research is currently underway to find other possible ways to make improvements. In the following article, we present less known checkpoint inhibitors which have therapeutic potential in the near future.

Keywords: checkpoint inhibitors, immunotherapy, LAG-3, TIM-3, TIGIT, VISTA.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopecký J. New potential checkpoint inhibitors in cancer therapy. Onkologie. 2022;16(3):115-117. doi: 10.36290/xon.2022.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yi M, Yu S, Qin S, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):47. Go to original source... Go to PubMed...
    2. Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393-405. Go to original source... Go to PubMed...
    3. Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2011;344:269-278. Go to original source... Go to PubMed...
    4. Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115(2):170-178. Go to original source... Go to PubMed...
    5. Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80-96.Další literatura u autora a na www.onkologiecs.cz Go to original source... Go to PubMed...
    6. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917-927. Go to original source... Go to PubMed...
    7. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383-3392. Go to original source... Go to PubMed...
    8. Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190(9):4899-4909. Go to original source... Go to PubMed...
    9. Burova E, Hermann A, Dai J, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019;18(11):2051-2062. Go to original source... Go to PubMed...
    10. Huang RY, Eppolito C, Lele S, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359-27377. Go to original source... Go to PubMed...
    11. Guo M, Qi F, Rao Q, et al. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Frontiers in Immunology. 2021;12(4196). Go to original source... Go to PubMed...
    12. Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. Journal of Clinical Oncology. 2017;35(15_suppl):9520-9520. Go to original source...
    13. Hong DS, Schoffski P, Calvo A, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 2018;36(15_suppl): 3012-3012. Go to original source...
    14. Uboha NV, Milhem MM, Kovacs C, et al. Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology. 2019;37(15_suppl):2553-2553. Go to original source...
    15. Papadopoulos KP, Lakhani NJ, Johnson ML, et al. First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 2019;37(15_suppl):2508-2508. Go to original source...
    16. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine. 2022;386(1):24-34. Go to original source... Go to PubMed...
    17. LaMotte-Mohs R, Shah K, Smith D, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Research. 2016;76(14 Supplement):3217-3217. Go to original source...
    18. Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8:71. Go to original source... Go to PubMed...
    19. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871): 536-541. Go to original source... Go to PubMed...
    20. van de Weyer PS, Muehlfeit M, Klose C, et al. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun. 2006;351(2):571-576. Go to original source... Go to PubMed...
    21. He Y, Cao J, Zhao C, et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets and therapy. 2018;11:7005-7009. Go to original source... Go to PubMed...
    22. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44(5):989-1004. Go to original source... Go to PubMed...
    23. Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Molecular Cancer. 2019;18(1):155. Go to original source... Go to PubMed...
    24. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1): 97-111. Go to original source... Go to PubMed...
    25. Wang Z, Chen J, Wang M, et al. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia. Frontiers in Immunology. 2021;12(1098). Go to original source... Go to PubMed...
    26. Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. Journal for immunotherapy of cancer. 2020;8(1):e000911. Go to original source... Go to PubMed...
    27. Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57. Go to original source... Go to PubMed...
    28. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245-1252. Go to original source... Go to PubMed...
    29. Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125(5):2046-2058. Go to original source... Go to PubMed...
    30. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869-3875. Go to original source... Go to PubMed...
    31. Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother. 2018;67(11):1659-1667. Go to original source... Go to PubMed...
    32. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(4):1537-1541. Go to original source... Go to PubMed...
    33. Le Mercier I, Chen W, Lines JL, et al. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014;74(7):1933-1944. Go to original source... Go to PubMed...
    34. Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692-1697. Go to original source... Go to PubMed...
    35. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269-274. Go to original source... Go to PubMed...
    36. Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500-2506. Go to original source... Go to PubMed...
    37. Castellanos JR, Purvis IJ, Labak CM, et al. B7-H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66-75.
    38. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409-418. Go to original source... Go to PubMed...
    39. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34(11):556-563. Go to original source... Go to PubMed...
    40. Han P, Goularte OD, Rufner K, et al. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol. 2004;172(10):5931-5939. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.